BRCA2 and ovarian serous adenocarcinoma: As a single agent, olaparib has recently been approved for ovarian cancer therapy by the US Food and Drug Administration (FDA) and European Commission in patients with platinum‐sensitive, recurrent, high‐grade serous ovarian cancer with BRCA1 or BRCA2 mutations 36, 37.